The researchers developed an antibody, Y01, that specifically targets tau-acK280 and solved the crystal structure of the Y01-acK280 peptide complex; upon interaction with acetylated tau protein aggregates, Y01 prevented the progression of tauopathy and increased neuronal viability. The gene discussed is MAPT; the disease is tauopathy.